NASDAQ:CTKB Cytek Biosciences (CTKB) Stock Price, News & Analysis $4.00 +0.05 (+1.14%) Closing price 03:59 PM EasternExtended Trading$4.04 +0.04 (+1.00%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cytek Biosciences Stock (NASDAQ:CTKB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytek Biosciences alerts:Sign Up Key Stats Today's Range$3.94▼$4.0650-Day Range$3.36▼$4.9452-Week Range$2.37▼$6.18Volume570,663 shsAverage Volume816,400 shsMarket Capitalization$517.22 millionP/E RatioN/ADividend YieldN/APrice Target$5.69Consensus RatingHold Company Overview Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods. The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters. These instruments are complemented by a range of pre-formulated antibody panels, custom reagent kits and data analysis software. Cytek’s offerings are tailored to diverse applications such as immunophenotyping, cell signaling studies, oncology research and translational medicine. Founded in 2014 and headquartered in Fremont, California, Cytek Biosciences has established a global distribution network serving academic institutions, biopharmaceutical companies and clinical laboratories across North America, Europe and Asia. The company completed its initial public offering in mid-2021, marking a key milestone in its growth strategy. Under the leadership of Dr. Ping Wang, Cytek continues to invest in research and development to extend its spectral cytometry capabilities and broaden its product pipeline. With a focus on advancing single-cell profiling, Cytek Biosciences aims to accelerate discoveries in immunology, cell therapy and personalized medicine. Its integrated hardware, reagents and software ecosystem provides end users with streamlined workflows, rapid assay development and robust data quality, supporting cutting-edge research and clinical investigations worldwide.AI Generated. May Contain Errors. Read More Cytek Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreCTKB MarketRank™: Cytek Biosciences scored higher than 35% of companies evaluated by MarketBeat, and ranked 703rd out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingCytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCytek Biosciences has a consensus price target of $5.69, representing about 43.1% upside from its current price of $3.98.Amount of Analyst CoverageCytek Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Cytek Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytek Biosciences are expected to grow in the coming year, from ($0.27) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -6.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -6.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cytek Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.69% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 12.37, which indicates bearish sentiment.Change versus previous monthShort interest in Cytek Biosciences has recently decreased by 4.40%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cytek Biosciences this week, compared to 2 articles on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.36% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cytek Biosciences' insider trading history. Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTKB Stock News HeadlinesAnalysts Set Cytek Biosciences, Inc. (NASDAQ:CTKB) Price Target at $5.69May 19 at 3:52 AM | americanbankingnews.comCytek Biosciences, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comJune 12: The Biggest Buying Spree in History?Former tech executive and angel investor Jeff Brown - who picked Bitcoin, Tesla, and Nvidia before surges of up to 52,400% - says the SpaceX IPO on June 12 could trigger the biggest buying spree in market history. Brown is urging investors to get positioned before the IPO date arrives, when shares could double or more on the first day of trading.May 22 at 1:00 AM | Brownstone Research (Ad)Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff PressuresMay 9, 2026 | tipranks.comCytek (CTKB) Q1 2026 Earnings Call TranscriptMay 8, 2026 | finance.yahoo.comCytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comCytek Biosciences Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comCytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | globenewswire.comSee More Headlines CTKB Stock Analysis - Frequently Asked Questions How have CTKB shares performed this year? Cytek Biosciences' stock was trading at $5.05 on January 1st, 2026. Since then, CTKB stock has decreased by 21.3% and is now trading at $3.9750. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07. The business earned $44.14 million during the quarter, compared to analyst estimates of $44.23 million. Cytek Biosciences had a negative net margin of 36.25% and a negative trailing twelve-month return on equity of 10.07%. Read the conference call transcript. How will Cytek Biosciences' stock buyback program work? Cytek Biosciences' Board of Directors authorized a stock buyback plan on Monday, December 30th 2024, which allows the company to buy back $50,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 5.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued. When did Cytek Biosciences IPO? Cytek Biosciences (CTKB) raised $248 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share. Who are Cytek Biosciences' major shareholders? Cytek Biosciences' top institutional investors include Dimensional Fund Advisors LP (2.06%), Bank of America Corp DE (0.78%), Bank of New York Mellon Corp (0.47%) and Principal Financial Group Inc. (0.41%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod and William D Mccombe. View institutional ownership trends. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytek Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings5/07/2026Today5/22/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 11 days, CTKB's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:CTKB CIK1831915 Webwww.cytekdev.com Phone877-922-9835FaxN/AEmployees500Year Founded1992Price Target and Rating Average Price Target for Cytek Biosciences$5.69 High Price Target$7.50 Low Price Target$4.75 Potential Upside/Downside+43.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.54 million Net Margins-36.25% Pretax Margin-17.61% Return on Equity-10.07% Return on Assets-7.56% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.07 Sales & Book Value Annual Sales$204.17 million Price / Sales2.50 Cash FlowN/A Price / Cash FlowN/A Book Value$2.54 per share Price / Book1.56Miscellaneous Outstanding Shares129,143,000Free Float115,764,000Market Cap$510.76 million OptionableOptionable Beta1.22 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CTKB) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
